A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer's disease

被引:115
作者
Crawford, FC
Freeman, MJ
Schinka, JA
Abdullah, LI
Gold, M
Hartman, R
Krivian, K
Morris, MD
Richards, D
Duara, R
Anand, R
Mullan, MJ
机构
[1] Univ S Florida, Roskamp Inst, Tampa, FL 33613 USA
[2] Novartis Pharmaceut Corp, E Hanover, NJ USA
[3] Mt Sinai Med Ctr, Miami Beach, FL 33140 USA
[4] Bristol Myers Squibb Co, Princeton, NJ USA
关键词
D O I
10.1212/WNL.55.6.763
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To investigate whether or not a coding polymorphism in the cystatin C gene (CST3) contributes risk for AD. Design: A case-control genetic association study of a Caucasian dataset of 309 clinic- and community-based cases and 134 community-based controls. Results: The authors find a significant interaction between the GG genotype of CST3 and age/age of onset on risk for AD, such that in the over-80 age group the GG genotype contributes two-fold increased risk for the disease. The authors also see a trend toward interaction between APOE epsilon 4-carrying genotype and age/age of onset in this dataset, but in the case of APOE the risk decreases with age, Analysis of only the community-based cases versus controls reveals a significant three-way interaction between APOE, CST3 and age/age of onset. Conclusion: The reduced or absent risk for AD conferred by APOE in older populations has been well reported in the literature, prompting the suggestion that additional genetic risk factors confer risk for later-onset AD. In the author's dataset the opposite effects of APOE and CST3 genotype on risk for AD with increasing age suggest that CST3 is one of the risk factors for later-onset AD. Although the functional significance of this coding polymorphism has not yet been reported, several hypotheses can be proposed as to how variation in an amyloidogenic cysteine protease inhibitor may have pathologic consequences for AD.
引用
收藏
页码:763 / 768
页数:6
相关论文
共 45 条
  • [1] BALBIN M, 1993, HUM GENET, V92, P206
  • [2] Cellular processing of the amyloidogenic cystatin C variant of hereditary cerebral hemorrhage with amyloidosis, Icelandic type
    Benedikz, E
    Merz, GS
    Schwenk, V
    Johansen, TE
    Wisniewski, HM
    Rushbrook, JI
    [J]. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 1999, 6 (03): : 172 - 182
  • [3] Bickeboller H, 1997, AM J HUM GENET, V60, P439
  • [4] Intracellular accumulation of the amyloidogenic L68Q variant of human cystatin C in NIH/3T3 cells
    Bjarnadottir, M
    Wulff, BS
    Sameni, M
    Sloane, BF
    Keppler, D
    Grubb, A
    Abrahamson, M
    [J]. JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY, 1998, 51 (06): : 317 - 326
  • [5] ApoE-4 and age at onset of Alzheimer's disease: The NIMH genetics initiative
    Blacker, D
    Haines, JL
    Rodes, L
    Terwedow, H
    Go, RCP
    Harrell, LE
    Perry, RT
    Bassett, SS
    Chase, G
    Meyers, D
    Albert, MS
    Tanzi, R
    [J]. NEUROLOGY, 1997, 48 (01) : 139 - 147
  • [6] Alpha-2 macroglobulin is genetically associated with Alzheimer disease
    Blacker, D
    Wilcox, MA
    Laird, NM
    Rodes, L
    Horvath, SM
    Go, RCP
    Perry, R
    Watson, B
    Bassett, SS
    McInnis, MG
    Albert, MS
    Hyman, BT
    Tanzi, RE
    [J]. NATURE GENETICS, 1998, 19 (04) : 357 - 360
  • [7] Boston PF, 1999, INT J GERIATR PSYCH, V14, P761, DOI 10.1002/(SICI)1099-1166(199909)14:9<761::AID-GPS14>3.0.CO
  • [8] 2-H
  • [9] Gender-specific association of the angiotensin converting enzyme gene with Alzheimer's disease
    Crawford, F
    Abdullah, L
    Schinka, J
    Suo, ZM
    Gold, M
    Duara, R
    Mullan, M
    [J]. NEUROSCIENCE LETTERS, 2000, 280 (03) : 215 - 219
  • [10] The butyrylcholinesterase gene is neither independently nor synergistically associated with late-onset AD in clinic- and community-based populations
    Crawford, F
    Fallin, D
    Suo, Z
    Abdullah, L
    Gold, M
    Gauntlett, A
    Duara, R
    Mullan, M
    [J]. NEUROSCIENCE LETTERS, 1998, 249 (2-3) : 115 - 118